拉替拉韦/恩曲他滨/替诺福韦联合方案一线治疗2型人类免疫缺陷病毒感染:一项2期非对照试验(ANRS 159 HIV-2)
该2期非对照试验纳入30例未接受抗逆转录病毒治疗的HIV-2感染者,评估含拉替拉韦方案。48周复合终点成功率为40%(95%CI 22.7%-59.4%),失败主要因CD4增益不足100 cells/μL(占50%)。含拉替拉韦的抗逆转录病毒治疗是HIV-2一线治疗的安全选择,成功率与蛋白酶抑制剂相当。
要点
- 48周复合终点成功率为40%(95%CI 22.7%-59.4%)。
- 失败主要因CD4增益不足100 cells/μL,占50%。
- 未报告严重不良反应。
核心结论
- 含拉替拉韦的抗逆转录病毒治疗是HIV-2感染一线治疗的安全选择,成功率与蛋白酶抑制剂相当。
研究设计与样本
- 2期非对照试验纳入30例未接受抗逆转录病毒治疗的HIV-2成人感染者,基线中位CD4计数436 cells/μL(IQR 314-507 cells/μL),67%为女性。
主要发现
- 48周复合终点成功率为40%(95%CI 22.7%-59.4%)。
- 失败主要因CD4增益不足100 cells/μL,占50%。
- 87%的参与者uspVL低于5 copies/mL,12%的参与者PCR总DNA超过6拷贝。
- 中位CD4增益为87 cells/μL(IQR 38-213 cells/μL;n=28)。
- 未报告严重不良反应。
临床怎么用
- 作者认为含拉替拉韦的抗逆转录病毒治疗是HIV-2感染一线治疗的安全选择,成功率与蛋白酶抑制剂相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New options for first-line treatment of human immunodeficiency virus type 2 (HIV-2) infection are needed. We evaluated an integrase inhibitor (raltegravir)-containing regimen. METHODS: Antiretroviral therapy (ART)-naive adults with symptomatic infection by HIV-2 only, CD4 count <500 cells/μL or CD4 decrease >50 cells/μL/year over the past 3 years, or a confirmed plasma HIV-2 RNA (pVL) load ≥100 copies/mL were eligible for this noncomparative trial. The composite primary endpoint was survival at 48 weeks without any of the following: CD4 gain from baseline <100 cells/μL, confirmed pVL ≥40 copies/mL from week 24, raltegravir permanent discontinuation, or incident B or C event. HIV-2 ultrasensitive pVL (uspVL) and total DNA were assessed using in-house polymerase chain reaction (PCR) assays. RESULTS: Baseline median CD4 count of 30 enrolled individuals (67% women) was 436 cells/µL (interquartile range [IQR], 314-507 cells/µL); pVL was ≥40 copies/mL in 67% of them, uspVL was ≥5 copies/mL in 92%, and total DNA was >6 copies by PCR in 32%. At week 48, the composite endpoint of success was reached in 40% [95% confidence interval, 22.7%-59.4%]. Failure was mainly (50%) due to CD4 gain <100 cells/µL; uspVL was <5 copies/mL in 87% and total DNA >6 copies by PCR in 12% of participants. Median CD4 gain was 87 cells/µL (IQR, 38-213 cells/µL; n = 28). No serious adverse reactions were reported. CONCLUSIONS: Raltegravir-containing ART is a safe option for first-line treatment of HIV-2 infection, yielding a comparable success rate to protease inhibitors. CLINICAL TRIALS REGISTRATION: NCT 01605890.
引用
- Matheron S, Descamps D, Gallien S, et al. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis. 2018. PMID: 29590335. doi:10.1093/cid/ciy245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。